title: [Long-term fate of pituitary dwarfs treated with growth hormone].
abstract: A questionnaire having been mailed to 50 hypopituitary patients aged 18 to 36 years (m 21.7 +/- 3.4) previously treated with human growth hormone for at least 3 years, 44 answers have been received. The final height is 2.1 +/- 0.9 standard deviations below the average. However 57% of the patients consider it is sufficient. The smallness is felt as a handicap by 20% only of these adults, though 88% had suffered for it during their adolescence. The treatment is retrospectively considered as useful and acceptable by 68%, heavy but useful by 25%, heavy and useless by 7%, without correlation with the results. Only 41% are satisfied with their school achievements. However, more than two thirds of patients had severe school difficulties at the time of onset of the treatment. Actually 75% of the patients are professionally qualified, among whom 36% have achieved high school, and most have an educational level similar to that of their parents or even higher. But 41% only have an employment, 27% are still students and 32% are unemployed. The way of life of the young hypopituitary adults is severely affected: 6 only are married or living with a mate, 11 only write they have occasional sexual experiences, 16 remain completely alone. In contrast, leisure activities are good in more than 90%. A score taking all these data into consideration to evaluate their way of life shows, among the 43 complete answers to the questionnaire, 16% with excellent results, 49% with a rather good social status and 35% with poor final result.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Service et Consultation d'Endocrinologie Pédiatrique, Hôpital Saint-Vincent-de-Paul, Paris.
authors.forename: J C
authors.initials: JC
authors.lastname: Job
authors.forename: J
authors.initials: J
authors.lastname: Chicaud
authors.forename: J E
authors.initials: JE
authors.lastname: Toublanc
authors.forename: J L
authors.initials: JL
authors.lastname: Chaussain
authors.forename: P
authors.initials: P
authors.lastname: Garnier
authors.forename: J
authors.initials: J
authors.lastname: Vassal
authors.forename: A
authors.initials: A
authors.lastname: Rolland
authors.forename: N
authors.initials: N
authors.lastname: Joab
authors.forename: B
authors.initials: B
authors.lastname: Chibaudel
authors.forename: P
authors.initials: P
authors.lastname: Canlorbe
mesh_terms: D000293:Adolescent; D000328:Adult; D001827:Body Height; D002648:Child; D004393:Dwarfism, Pituitary / Q000188:drug therapy* / Q000503:physiopathology / Q000534:rehabilitation; D005260:Female; D005500:Follow-Up Studies; D013006:Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D008019:Life Style; D008297:Male; D011795:Surveys and Questionnaires; D013997:Time Factors
chemical_list: D013006:Growth Hormone
vernacular_title: Le devenir à long terme des nains hypophysaires traités par l'hormone de croissance.